Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy

Lung Cancer

Volumn 68, Issue 2, 2010, Pages 269-272

  Tomizawa, Yoshio ^a   Fujita, Yuka ^b   Tamura, Atsuhisa ^c   Shirai, Masahiro ^d   Shibata, Satoshi ^e   Kawabata, Tsutomu ^f   Shibayama, Takuo ^g   Fukai, Shimao ^h   Kawahra, Masaaki ⁱ   Saito, Ryusei ^a  

^a National Nishigunma Hospital   (Japan)

^b Douhoku Hospital   (Japan)

^c TOKYO NATIONAL HOSPITAL   (Japan)

^d National Hospital Organization   (Japan)

^e Higasihiroshima Medical Center   (Japan)

^f National Hospital Organization   (Japan)

^g National Hospital Organization   (Japan)

^h National Hospital Organization   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy; Gefitinib; Non small cell lung cancer; Re challenge; Resistance; Responder

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DRUG EFFICACY; DRUG RECHALLENGE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS;

EID: 77950458802     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.06.025     Document Type: Article

References (23)

1. Ciardiello F., Toreora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
2. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21:2237-2246.
3. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
4. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
5. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonist in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595.
6. Costa D.B., Kobayashi S., Tenen D.G., Huberman M.S. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007, 58:95-103.
7. Kobayashi S., Boggon T.J., Dayaram T., Jänne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
8. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
9. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
10. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Ebi N., Kubota K., Nishiwaki Y., Hojo F., Matsumoto T., Kakinuma R., et al. Second-line chemotherapy for relapsed small cell lung cancer. Jap J Clin Oncol 1997, 27:166-169.
13. Yokouchi H., Yamazaki K., Kinoshita I., Konishi J., Asahina H., Sukoh N., et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007, 7:51.
14. Kurata T., Tamura H., Kaneda T., Nogami T., Uejima H., Asai G., et al. Effect of re-treatment with ('Iressa' ZD1839) after acquisition of resistance. Ann Oncol 2004, 15:173-177.
15. Yano S., Nakataki E., Ohtsuka S., Inayama M., Tomimoto H., Edakuni N., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable result from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2004, 15:107-111.
16. Yoshimoto A., Inuzuka K., Kita T., Kawashima A., Kasahara K. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007, 333:221-225.
17. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
18. Shepherd F.A., Rodrigues Pereira J., Ciulean T., Ciuleanu T., Tan E.H., Hirsh V., et al. Erlotinib in previous treated non-small cell lung cancer. N Engl J Med 2005, 353:123-132.
19. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
20. Cho B.C., Im C.K., Park M.S., Kim S.K., Chang J., Park J.P., et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25:2528-2533.
21. Wong A.S., Soong R., Seah S.B.K., Lim S.W., Chuah K.L., Nga M.E., et al. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008, 3:400-404.
22. Costa D., Nguyen K.S.H., Cho B.C., Sequist L.V., Jackman D.M., Riely G.J., et al. Effect of erlotinib in EGFR mutated non-small cell lung cancers with residence to gefitinib. Clin Cancer Res 2008, 14:7060-7067.
23. Mok T., Wu Y.L., Thongprasert S., Yang C.H., Chu D., Saijo N., et al. Phase III, randomised, open-label, first-line study of gefitinib (G) vs. carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS). Ann Oncol 2008, 19(SUPP1. 8). viii1, abs LBA2. 10.1093/annonc/mdn649.